Phase I trial of TX803 in colorectal cancer patients.
Phase of Trial: Phase I
Latest Information Update: 24 Mar 2017
At a glance
- Drugs TX 803 (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- 24 Mar 2017 New trial record
- 21 Mar 2017 According to a Tarrex Biopharma media release, US FDA has accepted IND application for TX803 in colorectal cancer. "